Description

BPC-157 / Ac-SDKP Research Formulation

A Peptide Combination for Investigating Cellular Signaling and Tissue Remodeling

This formulation combines BPC-157 with Ac-SDKP, a four-amino-acid fragment derived from the N-terminal region of thymosin β4. Supplied in capsule format, it contains BPC-157 arginate and salcaprozate sodium (SNAC).

Ac-SDKP is distinct from full-length thymosin β4. Research findings involving either compound should be interpreted according to the specific peptide, formulation, and experimental model studied.

BPC-157 Research Profile

BPC-157 is a synthetic peptide composed of 15 amino acids. Preclinical research has examined its effects on vascular signaling, cellular responses to injury, and tissue repair.

Areas of investigation include:

• Vascular signaling: Cell and animal studies have reported effects on VEGFR2 expression and the Akt-eNOS pathway, which are involved in endothelial function and blood vessel formation. Primary study
• Cell migration and survival: Research using tendon explants and cultured rat tendon fibroblasts has examined cell migration, survival under oxidative stress, and FAK-paxillin signaling. Primary study
• Tissue remodeling: Animal studies have evaluated collagen organization, tissue structure, and biomechanical outcomes following experimental tendon injury. Primary study

These findings describe specific experimental conditions and do not establish clinical benefits for this capsule formulation.

Ac-SDKP Research Profile

Ac-SDKP—also known as goralatide—is an N-acetylated tetrapeptide associated with research into fibrosis and hematopoietic cell-cycle regulation.

Areas of investigation include:

• Fibrotic signaling: Preclinical studies have examined collagen deposition, myofibroblast accumulation, and pathways associated with tissue fibrosis. A mouse model of renal injury reported reduced fibrosis following Ac-SDKP treatment. Primary study
• Hematopoietic regulation: Ac-SDKP has been studied for its effects on the entry of hematopoietic stem cells into the cell cycle and for potential protection during chemotherapy. Human findings have varied across treatment settings. Early clinical study, subsequent randomized trial

Combination Research Rationale

The individual research profiles of BPC-157 and Ac-SDKP provide a rationale for investigating how vascular signaling, cell migration, and extracellular matrix regulation interact.

Potential laboratory questions include:

• Whether combined exposure produces different cellular responses from either peptide alone.
• How the combination affects markers of angiogenesis, fibroblast activity, and collagen turnover.
• How formulation variables influence peptide stability, release, and availability in a defined experimental system.

Complementary research interests do not establish synergistic activity. Any combined effect requires direct evaluation.

Evidence and Formulation Context

The studies cited above concern individual peptides and specific experimental preparations. They do not establish the stability, oral bioavailability, safety, or efficacy of this capsule combination. The inclusion of SNAC should not be interpreted as proof of systemic peptide delivery.

Clinical findings involving full-length thymosin β4 also cannot be directly applied to Ac-SDKP. For example, the SEER-1 study evaluated a thymosin β4 ophthalmic solution, a different peptide preparation and route of administration. SEER-1 publication

Product Specifications

• Product name: BPC-157 / Ac-SDKP Research Formulation
• Listed peptide amounts: BPC-157 500 mcg; Ac-SDKP 2.5 mg
• BPC-157 form: Arginate salt
• Additional formulation component: Salcaprozate sodium (SNAC)
• Format: Capsules
• Count: 60 capsules
• SKU: BPTB-CAP-102.5MG
• Brand: Simple Supplements

Research Use Only

For laboratory research and educational reference only. Not for human consumption, therapeutic use, or use as a dietary supplement. This product is not an FDA-approved drug. Purchasers are responsible for ensuring that its acquisition, handling, and use comply with applicable laws and institutional requirements.